417 filings
D
AVTX
Avalo Therapeutics Inc
9 Apr 24
$199.98 mm in equity / options, sold $130.60 mm, 25 investors
4:58pm
10-K
2023 FY
AVTX
Avalo Therapeutics Inc
Annual report
29 Mar 24
4:05pm
8-K
AVTX
Avalo Therapeutics Inc
29 Mar 24
Avalo Reports 2023 Financial Results and Provides Business Updates
4:02pm
DEFA14A
AVTX
Avalo Therapeutics Inc
28 Mar 24
Additional proxy soliciting materials
6:26am
8-K
AVTX
Avalo Therapeutics Inc
28 Mar 24
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
6:08am
8-K
rng zok55orf3j
31 Jan 24
Other Events
4:01pm
8-K
4hb2kzs ug2alpexv
28 Dec 23
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
5:05pm
8-K
wrf1jw
20 Dec 23
Submission of Matters to a Vote of Security Holders
4:01pm
DEFA14A
qhzj4v
7 Dec 23
Additional proxy soliciting materials
7:02am
8-K
c5l240s aq3icj8mo
7 Dec 23
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
7:01am
8-K
kge5yh40x0sw5c
16 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:15am
8-K
49zs6
9 Nov 23
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
7:04am
8-K
iaiv501cxmrs2qrg qt
31 Oct 23
Avalo Completes Divestiture of AVTX-800 Series
7:21am
ARS
yo4hd
19 Oct 23
Annual report to shareholders
4:15pm
DEFA14A
g8pdkstgew249
19 Oct 23
Additional proxy soliciting materials
4:06pm
8-K
fvp22j6rp9whzl
17 Oct 23
Amendments to Articles of Incorporation or Bylaws
4:02pm
8-K
8wrr1wvmd a1u80rrl
3 Oct 23
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:05pm